Ultragenyx Pharmaceutical
RARE • NASDAQ
Ultragenyx Pharmaceutical is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Emil D. Kakkis, with a market cap of $2.4B.
Market Cap$2.4B
Employees1.3K
CEOEmil D. Kakkis
CountryUnited States of America
Healthcare
Biotechnology
Next EarningsMay 5, 2026 · In 1 weekAfter Market Close · Q1 2026
Financials
Ultragenyx Pharmaceutical FAQ
Common questions about Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical is scheduled to report earnings for Q1 2026 on May 5, 2026 after market close. Analysts estimate revenue of $159.3M.
Ultragenyx Pharmaceutical has approximately 1,276 employees.